BioPicture – Biologic mapping for treatment individualisation in rectal cancer by functional magnetic resonance
- Prosjektnummer
- 2016050
- Ansvarlig person
- Kathrine Røe Redalen
- Institusjon
- Akershus universitetssykehus HF
- Prosjektkategori
- Forskerstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis
NEI
NEI
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer.
Cancer Immunol Immunother 2020 Mar;69(3):355-364. Epub 2019 des 31
PMID: 31893287
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer.
Transl Oncol 2019 Aug;12(8):1038-1044. Epub 2019 mai 27
PMID: 31146167
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer.
BMC Cancer 2019 May 23;19(1):488. Epub 2019 mai 23
PMID: 31122213
Comparison of Intravoxel incoherent motion imaging and multiecho dynamic contrast-based MRI in rectal cancer.
J Magn Reson Imaging 2019 Oct;50(4):1114-1124. Epub 2019 apr 4
PMID: 30945379
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer.
Transl Oncol 2019 Jan;12(1):76-83. Epub 2018 sep 29
PMID: 30273860
An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer.
J Extracell Vesicles 2019;8(1):1567219. Epub 2019 jan 29
PMID: 30728923
Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis.
PLoS One 2018;13(1):e0181912. Epub 2018 jan 19
PMID: 29357362
Learning radiation oncology in Europe: Results of the ESTRO multidisciplinary survey.
Clin Transl Radiat Oncol 2018 Feb;9():61-67. Epub 2018 feb 8
PMID: 29594252
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.
Br J Cancer 2018 May;118(10):1322-1328. Epub 2018 apr 26
PMID: 29695770
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival.
Acta Oncol 2017 Jun;56(6):813-818. Epub 2017 feb 17
PMID: 28464745
Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor Ktrans and ΔR2* peak are significantly associated with lymph node metastasis.
J Magn Reson Imaging 2017 Jul;46(1):194-206. Epub 2016 des 21
PMID: 28001320
Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.
Clin Exp Metastasis 2017 01;34(1):51-62. Epub 2016 nov 3
PMID: 27812769
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.
Cancer Res Treat 2017 Apr;49(2):374-386. Epub 2016 jul 28
PMID: 27488871
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.
J Enzyme Inhib Med Chem 2016 Oct;31(5):779-86. Epub 2015 aug 5
PMID: 26244271
High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.
Radiother Oncol 2016 Feb;118(2):393-8. Epub 2015 des 17
PMID: 26705680
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol 2016 Jun;119(3):505-11. Epub 2016 mar 8
PMID: 26968754
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.
Oncotarget 2016 Jun 07;7(23):34907-17.
PMID: 27145458
Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells.
Heliyon 2016 May;2(5):e00104. Epub 2016 mai 5
PMID: 27441277
Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
BMC Cancer 2016 Jul 26;16():531. Epub 2016 jul 26
PMID: 27461218
Circulating Markers of Immunogenicity and Metastasis in Combined-Modality Treatment of Rectal Cancer
- Disputert:
- desember 2017
- Hovedveileder:
- Kathrine Røe Redalen
- Endre Grøvik Prosjektdeltaker
- Kjell-Inge Gjesdal Prosjektdeltaker
- Lars Gustav Lyckander Prosjektdeltaker
- Stein Harald Holmedal Prosjektdeltaker
- Anne Negard Prosjektdeltaker
- Hanna Abrahamsson Doktorgradsstipendiat (annen finansiering)
- Sebastian Meltzer Doktorgradsstipendiat (annen finansiering)
- Kine Mari Bakke Doktorgradsstipendiat (annen finansiering)
- Anne Hansen Ree Forskningsgruppeleder
- Kathrine Røe Redalen Prosjektleder
- Marius Bornstein Prosjektdeltaker
- Christin Johansen Prosjektdeltaker
- Woldegabriel Melles Prosjektdeltaker
- Tryggve Storås Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport